These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32256521)

  • 1. Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer.
    Kieffer Y; Bonneau C; Popova T; Rouzier R; Stern MH; Mechta-Grigoriou F
    Front Genet; 2020; 11():219. PubMed ID: 32256521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer.
    Jönsson JM; Bååth M; Björnheden I; Sahin ID; Måsbäck A; Hedenfalk I
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
    Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
    J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
    Dong F; Davineni PK; Howitt BE; Beck AH
    Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.
    Takaya H; Nakai H; Sakai K; Nishio K; Murakami K; Mandai M; Matsumura N
    Gynecol Oncol; 2020 Feb; 156(2):415-422. PubMed ID: 31785864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas.
    Milanesio MC; Giordano S; Valabrega G
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
    Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
    JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
    Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
    Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
    Mittempergher L
    Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    Vanderstichele A; Busschaert P; Olbrecht S; Lambrechts D; Vergote I
    Eur J Cancer; 2017 Nov; 86():5-14. PubMed ID: 28950147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.
    Kreuzinger C; Gamperl M; Wolf A; Heinze G; Geroldinger A; Lambrechts D; Boeckx B; Smeets D; Horvat R; Aust S; Hamilton G; Zeillinger R; Cacsire Castillo-Tong D
    Cancer Lett; 2015 Jul; 362(2):218-28. PubMed ID: 25862976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whence High-Grade Serous Ovarian Cancer.
    Kohn EC; Ivy SP
    Am Soc Clin Oncol Educ Book; 2017; 37():443-448. PubMed ID: 28561656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathology and proteomics are synergistic for High-Grade Serous Ovarian Cancer platinum response prediction.
    Kilim O; Olar A; Biricz A; Madaras L; Pollner P; Szállási Z; Sztupinszki Z; Csabai I
    medRxiv; 2024 Jun; ():. PubMed ID: 38883738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell Origins of High-Grade Serous Ovarian Cancer.
    Kim J; Park EY; Kim O; Schilder JM; Coffey DM; Cho CH; Bast RC
    Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30424539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer.
    Lecuelle J; Boidot R; Mananet H; Derangère V; Albuisson J; Goussot V; Arnould L; Tharin Z; Ray Coquard I; Ghiringhelli F; Truntzer C; Fumet JD
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.